Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest and the most important advances in anti-cancer drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. Each volume is devoted to the major advances in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The eighth volume of the series features chapters covering the following topics: - T cells in gastrointestinal cancers - The pharmacology of adjudin – a male contraceptive with anti-cancer properties - Manipulating the tumor microenvironment - Treatment of hepatocellular carcinoma - Gold-based compounds as potential anti-cancer drug candidates - Oral nanostructure drug delivery for anti-cancer treatment

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The ninth volume of the series features chapters covering the following topics: - New research on the therapeutic intervention of cancer and cancer drug delivery - Dabrafenib usage in melanoma therapy - Targeting autophagy in cancer therapy - Pro-apoptotic and anti-telomerase activity of naturally occurring compounds - CDK inhibitors - Oral nanostructure drug delivery for anti-cancer treatment

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry,in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The tenth volume of the series features chapters covering the following topics: - Challenges in the Management of Hepatoblastoma - The Emerging Role of Monocarboxylate Transporter-1 in Cancer - In-vitro Anti-Proliferative Assays and Techniques Used in Pre-Clinical Anti-Cancer Drug Discovery - Recent Advances in the Development of Mesoporous Anti-Cancer Drug Nanocarriers - Polyphenols and Cancer - Glioblastoma Multiforme - Cutting Edge Targeting Strategies Utilizing Nanotechnology in Breast Cancer Therapy

<p></p> Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. <p></p> The eleventh volume of the series focuses on reviews on targeted therapies and drug delivery systems. This volume covers the following topics: <p></p> - PI3K/Akt/mTOR Pathway in Acute Lymphoblastic Leukemia Targeted Therapies <p></p> - Polymeric Nanomedicines in Treatment of Breast Cancer: Review of Contemporary Research <p></p> - Treatment of Lung Cancer in the New Era <p></p> - Oral Administration of Cancer Chemotherapeutics Exploiting Self-Nanoemulsifying Drug Delivery System: Recent Progress and Application <p></p> - Targeting Approaches for the Diagnosis and Treatment of Cancer

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. This volume of the series focuses on reviews of treatments derived from natural sources (cannabinoid-based medicines and turmeric), immunotherapy, biomarkers for glioblastoma and some new drug targets for anti-cancer treatment. The reviews included in this volume are: - Cannabinoid-Based Anticancer Strategies: - The Beneficial Effects of Turmeric and Its Active Constituent in Cancer Treatment - Immunotherapy Approaches Focusing on Cancer Stem Cells - Immunotherapy for the Treatment of Hepatocellular Carcinoma - Role of Biomarkers in Developing Therapies for Glioblastoma Multiforme - Poly (ADP-ribose) Polymerases as New Drug Targets in Cancer Treatment

&amp;amp;amp;ldquo;Frontiers in CNS Drug Discovery&amp;amp;amp;rdquo; is an eBook series devoted to publishing the latest and the most important advances in Central Nervous System (CNS) drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in CNS drug design and discovery. Each volume is devoted to the major advances in CNS drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

“Frontiers in CNS Drug Discovery” is an eBook series devoted to publishing the latest and the most important advances in Central Nervous System (CNS) drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in CNS drug design and discovery. Each volume is devoted to the major advances in CNS drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Frontiers in CNS Drug Discovery is a book series devoted to publishing reviews which highlight the latest advances in drug design and discovery for disorders of the central nervous system (CNS). Eminent scientists write contributions on all areas of CNS drug design and drug discovery, including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series is essential reading for all pharmaceutical scientists involved in CNS drug design and discovery who wish to keep abreast of rapid and important developments in the field. The third volume of this series brings reviews on brain tumor treatment, neurodegeneration, hyperalgesia, cholinesterase inhibition and much more.

The development of new erythropoietic stimulating agents (ESAs) has significantly increased in recent years. Researchers are focused on different and interesting concepts, namely, methods to increase half-life of erythropoietin (EPO), finding different routes of administration and new ESA or modified EPO molecules. Scientific literature presents evidence that EPO has other effects beyond erythropoietic stimulation. These pleiotropic effects of EPO appear to result from the existence of two different EPO receptors (EPOR) with different affinities for EPO. The discovery of new EPO actions beyond the hematopoietic system has opened a new field of investigation with these agents. Several molecules have been developed to present the protective action, without the activation of the hematopoietic system. These agents can be potentially used in several diseases of the brain/central and peripheral nervous system, eye, heart and kidney. This volume of Frontiers in Drug Discovery includes a revision of articles on erythropoiesis and EPO gene regulation, microRNAs and their potential contribution to the development of new therapeutic strategies, animal models for studying kidney disease-associated anemia as well as benefits/risks of ESA therapy. The biological effects of new ESA molecules, heparin-binding erythropoietin and of pHBSP, and the potential applications of ESA, are also elicited in this volume. This volume is, therefore, a useful reference for medicinal chemists and hematologists interested in drug development and medicine related to ESAs.

Major depressive disorder (MDD) is a prevalent, chronic, and recurring mental disorder. This disorder is a leading source of disability worldwide, and is associated with excess mortality rates. Currently approved antidepressants primarily enhance, or otherwise modulate monoaminergic neurotransmission, without curing the disease. Evidence indicates that only one third of patients with MDD achieve remission after treatment with a first-line antidepressant agent. Research in the past two decades has provided valuable insights into the pathophysiological understanding of MDD. However, there is an acknowledged ‘translational gap’ in the field, and few genuinely novel antidepressants have been approved for the treatment of MDD. The Search for Anti Depressants provides readers an in-depth picture of the main pathophysiological mechanisms responsible for the development of MDD in patients. Chapters in the volume focus on possible strategies to spur the discovery of novel antidepressants. This book is an indispensable reference for mental health care providers, students at both under-graduate and graduate levels, and neuroscientists interested in the neurobiology of MDD and recent advances towards the discovery of next generation antidepressants.